Log in to save to my catalogue

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymph...

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymph...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2528813699

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Tisagenlecleucel therapy has shown promising efficacy for relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, relapses occur in 30–50% of patients. Determinants for CD19
pos
versus CD19
neg
relapses are poorly characterized. We report on 51 patients with R/R BCP-ALL (median age 17 years) infused w...

Alternative Titles

Full title

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2528813699

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2528813699

Other Identifiers

ISSN

0887-6924

E-ISSN

1476-5551

DOI

10.1038/s41375-021-01281-7

How to access this item